News & Updates

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

The orally bioavailable, investigational neuroactive steroid zuranolone appears to be beneficial in the treatment of insomnia, producing improvements in sleep measures, including sleep efficiency, duration of awakenings, and total sleep time in adults, according to the results of a phase I study.

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.